Articles tagged with "Drugs"
HawkEye drug-recognition tool aids law enforcement
January 5, 2008 The AcuNetx HawkEye law enforcement system, which magnifies and records tell-tale signs of drug intoxication in a suspect’s pupils, has been awarded two separate patents by the U.S. Patent and Trademark Office. The tool is now being used by highway patrol officers and at sobriety checkpoints across the U.S.A. (read more...)
Personal therapy sensory device sales to soar
August 22, 2007 As our lives become increasingly busy and stressful people are always on the look out for new ways to relax and find alternatives to drug therapy and conventional Western medicine. The result has been an increase in the number of people engaging in complementary and alternative medicine, which has in turn created a multi-million dollar industry for technologies aimed at delivering personal therapy and relaxation. (read more...)
Sugar is the key to the nicotine rush according to new research
July 27, 2007 Smoking and blood sugar levels are highly interrelated – nicotine causes the body to release satisfying levels of sugar into the bloodstream far faster than eating can, which explains its appetite-inhibiting effects. The results of low blood sugar levels in a quitting nicotine addict are also responsible for some of the most difficult withdrawal symptoms. Now it has been discovered that sugar is also a key element in the chemical reaction that causes a smoker to feel “high”. When nicotine molecules are received by neurotransmitter membranes, it’s sugar molecules that then act as a sort of hinge to open a gate in the cell membrane and send the "nicotine rush" nerve signal onward. (read more...)
New research reveals the effects of ecstasy on memory function
June 25, 2007 Research carried out at the University of Hertfordshire (U.K.) has revealed that ecstasy users have significantly impaired memory compared with non-ecstasy users. The research report suggests that the recreational use of ecstasy produces a moderate to large effect on short-term and long-term memory and verbal memory, but not on visual memory. In over three-quarters of ecstasy users, long and short-term verbal memory is below the average of non-ecstasy using controls. Perhaps even more alarming in an era of recreational drug experimentation, the researchers also found that memory impairment was unrelated to the total number of ecstasy tablets consumed. (read more...)
Recreational Drugs and their level of harm
March 24, 2007 Just how dangerous are recreational drugs and what’s the most effective way to classify drugs as the basis for law enforcement? With the technologies for creating new substances now well ahead of the law’s ability to even recognise them, it’s clearly time for a new way of doing things. Last year, the UK’s House of Commons Science and Technology Committee tabled a report entitled Drug classification: making a hash of it? which concluded that the current UK classification of drugs into A, B and C classes should be replaced with a new system more closely reflecting the harm they cause. One of the most striking findings of the report was that based on the committee’s assessment of harm, tobacco and alcohol (in red on the chart) would be ranked as more harmful than cannabis, LSD and ecstasy. The report also stated that, on the basis of harm, "alcohol would be classed as B bordering on A, while cigarettes would probably be in the borderline between B and C". Now a leading researcher on substance misuse has expressed concern that the proposed classification regime is too limited in its approach to serve as a basis for changes in the law. (read more...)
New drugs promise two days without sleep and improved alertness and cognitive powers
March 5, 2007 Two years ago, we wrote about the “time-shifting” drug, Modafinil that enables you to stay awake for 40+ hours with close to full mental capacity and with few side effects. The drug is a eugeroic and offers improved memory, mood enhancement, improved alertness and cognitive powers, and has a much smoother feel than amphetamines because they work differently. Popular Science is now reporting that we’re just about to see new forms of super eugeroic called armodafinil (Modafinil’s creator Cephalon is awaiting FDA approval for the drug), and a drug code-named CX717 from Cortex. Both drugs promise even longer periods of wakefulness, and in experiments with Ampakine CX717, sleep-deprived rhesus monkeys on the drug often outperformed their own well-rested but undrugged best efforts on mental-performance tests. While these drugs will be marketed to assist people with sleep disorders like narcolepsy, it’s their potential as recreational and workplace performance-enhancing drugs that make them worth watching. The times they are a changing … (read more...)
The Intellidrug tooth implant
February 2, 2007 Man has been producing and administering drugs since the neolithic period. Initially these drugs were administered orally mixed with a liquid with the advent of pills making inhalation and the intramuscular or intravenous injection following. These days, the majority of the world’s drugs are administered via pills – pills offer an accurate dosage, but they are so convenient that it’s often possible to forget when you’ve taken them. Chronically ill patients get muddled when constantly having to swallow different numbers of tablets at different times, while those with dementia simply cannot cope. Now EU researchers are developing a better, more accurate and more convenient way – a dental prosthesis capable of releasing accurate dosages into the mucous membranes in the mouth. As it can administer accurate micro amounts over continuous periods, the prosthesis overcomes the peak concentrations that occur with taking pills and even offers the ability to monitor and maintain consistent blood levels of any drug. What makes the Intellidrug prosthesis unique is that, unlike existing drug prostheses and implants, it is small enough to fit into two artificial molars. Inside the patient’s mouth, it is readily accessible and can easily be maintained and refilled. (read more...)
Discovery opens door for drugs for alcohol addiction
December 14, 2006 The connection between nicotine and alcohol has been known for some time, though the fact that alcoholism is ten times stronger among smokers than among non-smokers is not as widely known ... and it’s not just because many people smoke at parties. When sober alcoholics are tempted to fall off the wagon, the same receptor in their brain is stimulated as is activated by nicotine. This has been demonstrated in a doctoral dissertation at the Sahgrenska Academy at Göteborg University in Sweden. The discovery may lead to new treatment for alcohol abuse. (read more...)
The Molecular Condom - vaginal gel releases Anti-HIV drug when exposed to semen
December 13, 2006 Once likened to “taking a shower with a raincoat on”, the condom may be the safest method of protection during sex, but it significantly detracts from the experience. Last week we featured the spray-on condom designed to offer a better fit but we’re betting that new work being done by University of Utah scientists will get a lot of attention due to its likelihood of overcoming the many shortcomings of the condom. It is in fact a "molecular condom" for use by women. The liquid is vaginally inserted daily and prevents AIDS by turning into a gel-like coating and when exposed to semen, returning to liquid form and releasing an antiviral drug. The ultimate hope for this technology is to protect women and their unborn or nursing children from the AIDS virus, but the molecular condom is five years away from tests in humans and roughly 10 years until it might be in widespread use. (read more...)
Nanocarriers that can kill tumors with drugs and DNA
October 2, 2006 Singapore scientists have developed nanoparticles that can carry both small molecular anticancer drugs and nucleic acids simultaneously for improved cancer therapy. The uniqueness of the new technology from the Institute of Bioengineering and Nanotechnology (IBN) lies in the design of a special biodegradable carrier (cationic core-shell nanoparticle), which can enclose drug molecules and allow therapeutic nucleic acids to bind onto it. It can efficiently introduce DNA into a cell to be incorporated into its genetic make-up, i.e. induce high gene expression level, especially in both human and mouse breast cancer cell lines, and mouse breast cancer model. The co-delivery of small molecular drugs with nucleic acids can improve gene transfection efficiency, reduce side-effects of these drugs, and achieve the synergistic effect of drug and gene therapy for the more effective treatment of cancer. (read more...)
Drug-Free Solution from for insomnia sufferers
February 12, 2006 Approximately 30 million Americans suffer from chronic insomnia. Many of these people do not seek help for their sleep problems, while others rely on medications to help them sleep. Unfortunately, most of these approaches are not long-term solutions. The National Institutes of Health (NIH) released a State-of-the-Science statement concluding that cognitive behavioral therapy (CBT) is one of the most effective long-term treatments for chronic insomnia. In the past, insomnia sufferers have not had the option of behavioral therapy in the comfort of their homes. A new product called SleepKey is designed to bridge this gap by delivering CBT as a self-help modality. (read more...)
Potential HIV-AIDS cure - drug found to kill multiple HIV strains
February 9, 2006 Vanderbilt University, Brigham Young University and Ceragenix Pharmaceuticals have announced that one of a family of compounds, called Ceragenins (or CSAs) shows potent virucidal activity in in vitro laboratory tests against multiple strains of Human Immunodeficiency Virus (HIV), the virus that causes AIDS. CSAs were invented by Dr. Paul D. Savage of Brigham Young University's Department of Chemistry and Biochemistry and exclusively licensed to Ceragenix. In data previously presented by Dr. Savage and other researchers, CSAs have been shown to have broad spectrum antibacterial activity. Dr. Derya Unutmaz, Associate Professor of Microbiology and Immunology at the Vanderbilt University School of Medicine, tested several CSAs in his laboratory for their ability to kill HIV directly and whilst cautious, acknowledged that CSAs could be the breakthrough technology to combat HIV/AIDS researchers the world has been waiting for. (read more...)
Modafinil - the time-shifting drug
The wonders of pharmacology keep appearing regularly, each new drug seemingly too good to be true. In recent times there have been several killer apps for the drug industry – chemical substances that replace depression with a happy disposition or bolster a flagging sex drive to royal command performance (with encore) levels. Prozac and Viagra provided benefits so compelling they have entered everyday language and have a global following. Now there’s another “drug-most-likely-to-succeed” – this one enables you to stay awake for 40+ hours with close to full mental capacity with few side effects (read more...)
Drug-dispensing contact lenses
November 2, 2004 Scientists from the Singapore Institute of Bioengineering and Nanotechnology have invented a method of manufacturing polymeric lens materials that can be loaded with eye medication for ophthalmic drug delivery applications. Currently, when a person suffers from eye ailments they will be prescribed eye drops. However, 95% of the medication administered in this manner flows to where it is not needed. The drops usually mix with tears and drain into the nasal cavity, where they can flow through the blood stream to other organs and cause serious side effects. In addition, dosage through eye drops is inconsistent and difficult to regulate, as most of the drugs are released in an initial burst of concentration. To counter these problems researchers have been studying the use of contact lenses to deliver eye medication. One proposed method was to pre-soak the lenses in the drug solution, while another involved incorporating the drug solution in a hollow cavity made by bonding two separate pieces of lens material. However, neither of these methods proved very effective at delivering medication for extended periods of time. (read more...)
New contraceptive drug gains US administrative approval
Saturday October 11, 2003: An "extended-cycle" oral contraceptive that reduces the number of periods from 13 to 4 per year has been approved the U.S. Food and Drug Administration. Clinical trials have found "SEASONALE" has a comparable safety profile to a more traditional oral contraception.... (read more...)
